Evidence map›Paper›PMID 41459139›Full record

ArticleTherapeutics and clinical risk management2025

Prognostic Factors and Clinical Prediction Score for Progressive Respiratory Failure in Severe COVID-19 Pneumonia Patients Treated with Tocilizumab: A Multicenter Study.

Nantakarn Pongtarakulpanit, Kulapong Jayanama, Phichayut Phinyo, Waravudh Naothavorn, Siripat Nuprom, Dhanesh Pitidhammabhorn, Pipat Ngammisri, Pintip Ngamjanyaporn, Vichayhud Suthichatchawan, Lerkiat Wicharit and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutics and clinical risk management, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nantakarn PongtarakulpanitDivision of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.ORCID 0000-0002-1384-9834
Kulapong JayanamaChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.ORCID 0000-0002-4237-2756
Phichayut PhinyoCenter for Clinical Epidemiology and Clinical Statistics, Department of Family Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.ORCID 0000-0002-8543-6254
Waravudh NaothavornChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.ORCID 0000-0002-9431-6254
Siripat NupromChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.
Dhanesh PitidhammabhornChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.ORCID 0000-0002-4167-9334
Pipat NgammisriChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.ORCID 0009-0001-0203-7224
Pintip NgamjanyapornDivision of Allergy, Immunology and Rheumatology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.ORCID 0000-0001-7948-1748
Vichayhud SuthichatchawanDepartment of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Lerkiat WicharitBoromarajonani College of Nursing, Nakhon Ratchasima, Faculty of Nursing, Praboromarajchanok Institute, Nakhon Ratchasima, Thailand.ORCID 0009-0000-3053-7798
Kanin ThammavaranucuptChakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.ORCID 0000-0002-9873-3848

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: A proportion of COVID-19 pneumonia patients develop respiratory failure despite tocilizumab administration. This retrospective cohort study aimed to identify prognostic factors associated with progressive respiratory failure within 14 days among patients with severe COVID-19 pneumonia treated with Tocilizumab and to describe treatment outcomes. Patients and Methods: Patients with severe COVID-19 pneumonia were assessed, and their demographic, clinical, laboratory data, and prior treatment were collected on the day of tocilizumab administration. A multivariable Cox proportional hazard model was employed to identify prognostic factors. Results: Of the 109 patients, 32 (29.4%) progressed to respiratory failure. We identified the following independent prognostic factors for progressive respiratory failure: pulse oximetry saturation to fraction of inspired oxygen ratio (SpO Conclusion: In severe COVID-19 pneumonia patients treated with Tocilizumab, low SpO

Indexed as

clinical outcomesimmunomodulatory therapyinterleukin-6 blockaderisk stratificationsurvival analysis

Identifiers

PMID41459139
PMCPMC12742297

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.